Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VHL | P40337 | 20/20 | 0.80 |
| ▸ | ELOC | Q15369 | 11/20 | 0.80 |
| ▸ | ELOB | Q15370 | 11/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17951935 | 1.00 | VHL (0.80) | VHLELOCELOB | |
| SCHEMBL29843244 | 1.00 | VHL (0.80) | VHLELOCELOB | |
| SCHEMBL19888885 | 1.00 | VHL (0.80) | VHLELOCELOB | |
| SCHEMBL18090250 | 1.00 | VHL (0.80) | VHLELOCELOB | |
| SCHEMBL19875334 | 1.00 | VHL (0.80) | VHLELOCELOB | |
| SCHEMBL23098441 | 1.00 | VHL (0.80) | VHLELOCELOB | |
| SCHEMBL18088944 | 0.94 | VHL (0.73) | VHLELOCELOB | |
| SCHEMBL22291850 | 0.94 | VHL (0.73) | VHLELOCELOB | |
| SCHEMBL22291849 | 0.93 | VHL (0.77) | VHLELOCELOB | |
| SCHEMBL18063871 | 0.93 | VHL (0.77) | VHLELOCELOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 151 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4629981-A2 | SMALL MOLECULE DEGRADERS OF C-SRC KINASE | The Regents Of The University Of Michigan (US) | 2025-10-15 | — | — | EP | claimed |
| WO-2024145315-A1 | TARGETED PROTEIN DEGRADERS OF INDOLEAMINE 2,3-DIOXYGENASE 1 (IDO1) | NORTHWESTERN UNIVERSITY (US) | 2024-07-04 | — | — | WO | claimed |
| WO-2024123819-A2 | SMALL MOLECULE DEGRADERS OF C-SRC KINASE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-06-13 | — | — | WO | claimed |
| US-20220023431-A1 | PROTEOLYSIS-TARGETING CHIMERIC MOLECULES (PROTACS) THAT INDUCE DEGRADATION OF INDOLEAMINE 2,3-DIOXYGENASE (IDO) PROTEIN | NORTHWESTERN UNIVERSITY | 2022-01-27 | — | — | US | claimed |
| US-20260131010-A1 | MENIN PROTEOLYSIS TARGETING CHIMERAS (PROTACS) | UNIV TEXAS (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | UNIV YALE (US) | 2026-04-30 | — | — | US | disclosed |
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12569464-B2 | Protein-protein interaction inducing technology | ARVINAS OPERATIONS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-12552783-B2 | Modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-12491252-B2 | Substituted 3-amino-5-phenylbenzamide compounds as covalent inhibitors of enhancer zeste homolog 2 (EZH2) and proteolysis-targeting chimeric derivatives thereof (PROTACs) that induce degradation of EZH2 | NORTHWESTERN UNIVERSITY (US) | 2025-12-09 | — | — | US | disclosed |
| US-12492209-B2 | Substituted [1,2,4]triazolo[4,3-c]pyrimidines that induce degradation of embryonic ectoderm development (EED) protein | NORTHWESTERN UNIVERSITY (US) | 2025-12-09 | — | — | US | disclosed |
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-20170065719-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | ARVINAS OPERATIONS, INC. | 2017-03-09 | — | — | US | disclosed |
| WO-2017030814-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | Arvinas, Inc. (US) | 2017-02-23 | — | — | WO | disclosed |
| WO-2017030814-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | Arvinas, Inc. (US) | 2017-02-23 | — | — | WO | disclosed |
| WO-2017011371-A1 | MDM2-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS, INC (US) | 2017-01-19 | — | — | WO | disclosed |
| WO-2016146985-A1 | DERIVATIVES OF 1-[(CYCLOPENTYL OR 2-PYRROLIDINYL)CARBONYLAMINOMETHYL]-4-(1,3-THIAZOL-5-YL) BENZENE WHICH ARE USEFUL FOR THE TREATMENT OF PROLIFERATIVE, AUTOIMMUNE OR INFLAMMATORY DISEASES | UNIVERSITY OF DUNDEE (GB) | 2016-09-22 | — | — | WO | disclosed |
| US-20160214972-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2016-07-28 | — | — | US | disclosed |
| US-20160045607-A1 | ESTROGEN-RELATED RECEPTOR ALPHA BASED PROTAC COMPOUNDS AND ASSOCIATED METHODS OF USE | YALE UNIVERSITY | 2016-02-18 | — | — | US | disclosed |
| US-20140356322-A1 | Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | VHL 2471/4885ELOC 874/4885ELOB 451/4885 |
| US-20160214972-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ESRRA, MDM2 | VHL 9/4885ELOC 411/4885ELOB 434/4885 |
| US-20140356322-A1 | Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase | VHL, MDM2, STUB1 | VHL 1/4885ELOC 190/4885ELOB 241/4885 |
| US-20260131010-A1 | MENIN PROTEOLYSIS TARGETING CHIMERAS (PROTACS) | CRBN, UBE3C, PSME3 | VHL 72/4885ELOC 136/4885ELOB 432/4885 |
| US-12492209-B2 | Substituted [1,2,4]triazolo[4,3-c]pyrimidines that induce degradation of embryonic ectoderm development (EED) protein | EED, CUL3, PSME3 | VHL 2296/4885ELOC 42/4885ELOB 274/4885 |
| US-12569464-B2 | Protein-protein interaction inducing technology | STUB1, MDM2, XIAP | VHL 1421/4885ELOC 1029/4885ELOB 980/4885 |
| US-20220023431-A1 | PROTEOLYSIS-TARGETING CHIMERIC MOLECULES (PROTACS) THAT INDUCE DEGRADATION OF INDOLEAMINE 2,3-DIOXYGENASE (IDO) PROTEIN | IDO1, IDO2, KMO | VHL 2395/4885ELOC 926/4885ELOB 2065/4885 |
| US-12552783-B2 | Modulators of proteolysis and associated methods of use | CRBN, ADRM1, MDM2 | VHL 37/4885ELOC 2051/4885ELOB 1657/4885 |
| US-12491252-B2 | Substituted 3-amino-5-phenylbenzamide compounds as covalent inhibitors of enhancer zeste homolog 2 (EZH2) and proteolysis-targeting chimeric derivatives thereof (PROTACs) that induce degradation of EZH2 | EZH2, BAZ2A, BAZ2B | VHL 235/4885ELOC 514/4885ELOB 183/4885 |
| US-20160045607-A1 | ESTROGEN-RELATED RECEPTOR ALPHA BASED PROTAC COMPOUNDS AND ASSOCIATED METHODS OF USE | GPER1, PSMA3, ESR2 | VHL 7/4885ELOC 153/4885ELOB 325/4885 |
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, VHL, ADRM1 | VHL 2/4885ELOC 1043/4885ELOB 797/4885 |
| US-20170065719-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | BRPF3, STUB1, BRDT | VHL 11/4885ELOC 251/4885ELOB 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.